KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically active therapies KT-579 Phase 1 testing expected to begin in early 2026 WATERTOWN, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for

London, United Kingdom October 28, 2025, Swarm Oncology Ltd. (“Swarm Oncology” or “Swarm”), a biotechnology company pioneering novel T cell therapies to achieve long-term remission in patients with advanced solid cancers, is pleased to announce a research collaboration with a leading US clinic to further broaden the feasibility and manufacturing of research-scale Swarm-T cell preparations by using samples from patients treated in the clinic’s cancer vaccine studies. This research collaboration

Data Show Statistically Significant Improvements in Pain, Function and Tendon Structure in Appropriately Dosed PatientsGLASGOW, Scotland, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Causeway Therapeutics, a clinical-stage biotechnology company developing novel medicines for tendon disease, today announced positive topline data from its Phase 2 clinical trial evaluating TenoMiR® (CWT-001), a proprietary microRNA-29a (miR-29a) mimic, in patients with lateral epicondylitis (commonly known as tendinopathy o

Approvals received from World Health Organization and United States Adopted Names Council establishing “xelafaslatide” as nonproprietary name for ONL1204 Ophthalmic SolutionANN ARBOR, Mich., Oct. 28, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the first participant has been randomized in the company’s Phase 2 GALAXY trial. GALAXY is a globa

IBSRELA patients reported treatment satisfaction in real-world survey Post-hoc analysis of T3MPO-1 and T3MPO-2 studies demonstrates effectiveness of IBSRELA in reducing abdominal bloating for patients with IBS-C Analysis of electronic health records suggests IBSRELA may reduce burden to healthcare system WALTHAM, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-i

Basel, October 28, 2025 - Novartis today announced that it has successfully completed its acquisition of Tourmaline Bio, Inc. (“Tourmaline”). With the completion of the acquisition, shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline, have ceased trading on the Nasdaq Stock Market LLC and Tourmaline is now an indirect wholly owned subsidiary of Novartis. “The acquisition of Tourmaline Bio aligns with our strategy to deepen expertise in areas where Novartis can lead

Discovery and development of the first systemic therapeutics to deliver self-antigens directly to the thymus to harness the body’s natural mechanism to induce central tolerance Lead program in Type 1 diabetes is advancing toward the clinic, with pipeline opportunities in a broad range of autoimmune diseases Company appoints Jason F. Cole, experienced biotech leader and company builder, as Chief Executive Officer Oct. 28, 2025 -- Zag Bio™, Inc., a biotechnology company pioneering thymus-target

SPVN20 aims to restore visual acuity and aspects of color vision by creating an alternative light-signaling cascade in malfunctioning cone photoreceptors Delivered through a single intravitreal injection, SPVN20 targets prevalent retinal diseases with no existing standard of care independently of their causes 28 October 2025 – SparingVision (“the Company”), a clinical-stage genomic medicine company transforming the treatment of retinal diseases, today announced that the first patient has been s

Oct. 28, 2025 -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a late-breaking poster abstract at the American College of Rheumatology (ACR) Convergence 2025, taking place October 24–29 at McCormick Place Convention Center in Chicago, Illinois. The presentation will feature clinical data from the recently announced Phase IIa (ENX-CL-05-001) 3-month topline data readout for Allocetra

Oct. 27, 2025 -- MicrobiotiX Co., Ltd. (CEO Dongeun Yong), a company specializing in the development of novel bacteriophage therapeutics, announced on October 27 that it received Investigational New Drug (IND) approval from the Ministry of Food and Drug Safety (MFDS) on October 21 for MP101, its investigational bacteriophage therapy for patients with acute pneumonia. With this approval, MicrobiotiX becomes the first company in Korea to initiate a first-in-human (FIH) clinical trial for a bacte